PEA Ultra (Ultramicronized).

Ultramicronised and standard palmitoylethanolamide are the same fatty acid amide, differing in particle size and therefore in dissolution and uptake. Stacking them adds dose rather than adding a mechanism.

Palmitoylethanolamide acts largely through PPAR-alpha signalling in glial and mast cells, while luteolin is a flavonoid that stabilises mast cell granule release through a separate route. The two have been co-micronised in commercial formulas for years because the mechanisms sit side by side rather than overlapping.

Palmitoylethanolamide and oleamide are both fatty acid amides broken down by fatty acid amide hydrolase and related hydrolases. Co-dosing one occupies the enzyme and slows breakdown of the other.

Quercetin acts on the same mast cell stabilisation route as luteolin and is often used in its place. It works through granule release rather than through PPAR-alpha, so the two mechanisms sit alongside each other.

PEA and docosahexaenoic acid are both fatty acid derived signalling lipids that influence inflammatory resolution, PEA largely through PPAR-alpha and DHA through its own oxygenated mediators. A published combination study measured neurosteroid and neuroinflammatory markers with the pair rather than clinical endpoints, so the finding is marker-level. Practically, both are lipophilic and share the same fat-dependent absorption route.

PEA is a poorly water-soluble amide that absorbs better with dietary fat, and an omega-3 oil supplies exactly that lipid vehicle. Beyond the physical effect, both feed into resolution-phase lipid signalling from different substrates. The absorption half is settled chemistry; the additive signalling half is mechanistic rather than outcome-level.

Eicosapentaenoic acid competes with arachidonic acid at cyclooxygenase and lipoxygenase and yields less inflammatory mediators, a different lever from PEA's PPAR-alpha route. They are frequently co-formulated in nerve and joint comfort products. The evidence is mechanistic overlap, not a tested combination outcome.

Alpha-lipoic acid is a thiol redox cycler active in both aqueous and lipid compartments, while PEA signals mainly through PPAR-alpha and by raising endocannabinoid tone. The two are combined in nerve comfort formulas so often that the pairing is effectively a category convention. Mechanisms are separate, which is the argument for combining them.

Acetyl-L-carnitine donates acetyl groups and supports mitochondrial fatty acid transport, mechanisms unrelated to PEA's lipid signalling. Products aimed at nerve comfort routinely carry both. Neither depends on the other, so the pairing is additive rather than enabling.

B12 is a cofactor for methionine synthase and methylmalonyl-CoA mutase, and both reactions matter for normal nerve and myelin maintenance. It is a nutrient sufficiency question sitting alongside PEA's signalling role, not a pharmacological interaction with it. B12 accompanies PEA in nerve-support formulas for this reason.

5-methyltetrahydrofolate donates the methyl group that regenerates methionine from homocysteine, a reaction that has to run for normal methylation across the nervous system. That is a background nutrient requirement, independent of PEA's PPAR-alpha signalling. Both appear together in nerve formulas as complementary rather than interacting ingredients.

Pyridoxal 5-phosphate serves the decarboxylases that make several neurotransmitters and participates in sphingolipid metabolism, both relevant to normal nerve function. It is a cofactor requirement, not a partner in PEA's own mechanism. High chronic B6 intakes carry their own limits and should be counted on their own terms.

Boswellic acids are described as inhibiting 5-lipoxygenase and leukotriene formation, a target PEA does not use. Products aimed at joint comfort and mobility often carry both lipophilic ingredients together. The rationale is complementary mechanism, not a tested pair.

MSM is a small water-soluble sulfur compound used in joint comfort formulas, and PEA is a lipophilic signalling amide. There is no established mechanistic link between them beyond appearing in the same category of products. Stating that plainly is more useful than manufacturing a pathway.

PEA is often taken in the evening and is paired with melatonin in products aimed at comfort and rest together. The mechanisms do not intersect: melatonin acts at MT1 and MT2 receptors, PEA at PPAR-alpha. The pairing is a dosing-schedule convenience, and it should be described as one.

Magnesium modulates NMDA receptor activity and is required for normal muscle relaxation, unrelated to PEA's lipid signalling. The two appear together in comfort formulas. No combination evidence supports the pairing beyond the separate rationale for each.